Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Migraine and Headache

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

Eur J Cancer.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF

doi: 10.1016/j.ejca.2016.12.001.

Further Publications NeurologyFurther Publications Psychiatry

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons

Neurosurgery.

Aquilanti E, Brastianos PK

doi: 10.1093/neuros/nyaa095.

Multiple Sclerosis

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

Cell.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R

doi: 10.1016/j.cell.2018.08.011.

Further Publications NeurologyFurther Publications Psychiatry

T cells in patients with narcolepsy target self-antigens of hypocretin neurons

Nature.

Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, Jovic S, Jarrossay D, Mathis J, Zellini F, Becher B, Lanzavecchia A, Khatami R, Manconi M, Tafti M, Bassetti CL, Sallusto F

doi: 10.1038/s41586-018-0540-1.

Further Publications NeurologyFurther Publications Psychiatry

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Nat Med.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R

doi: 10.1038/s41591-019-0349-y.

RECOMMENDED

Further Publications NeurologyFurther Publications Psychiatry

Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum

★ 3 Recommended by Prof. Dr Christian Kamm, Faculty Member

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Ann Neurol.

Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC

doi: 10.1002/ana.25708.

Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis

Neurology.

Scheibe F, Prüss H, Mengel AM, Kohler S, Nümann A, Köhnlein M, Ruprecht K, Alexander T, Hiepe F, Meisel A

doi: 10.1212/

Multiple Sclerosis

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis

JAMA Neurol.

Knier B, Leppenetier G, Wetzlmair C, Aly L, Hoshi MM, Pernpeintner V, Biberacher V, Berthele A, Mühlau M, Zimmer C, Hemmer B, Korn T

doi: 10.1001/jamaneurol.

Related content

Vaccination Readiness in Multiple Sclerosis

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

T cells in patients with narcolepsy target self-antigens of hypocretin neurons

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum

Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis